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Oncogenic Ras induces inﬂammatory cytokine
production by upregulating the squamous cell
carcinoma antigens SerpinB3/B4
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Howard C. Crawford4 & Wei-Xing Zong1
Mounting evidence indicates that oncogenic Ras can modulate cell autonomous inﬂammatory
cytokine production, although the underlying mechanism remains unclear. Here we show that
squamous cell carcinoma antigens 1 and 2 (SCCA1/2), members of the Serpin family of
serine/cysteine protease inhibitors, are transcriptionally upregulated by oncogenic Ras via
MAPK and the ETS family transcription factor PEA3. Increased SCCA expression leads to
inhibition of protein turnover, unfolded protein response, activation of NF-kB and is essential
for Ras-mediated cytokine production and tumour growth. Analysis of human colorectal and
pancreatic tumour samples reveals a positive correlation between Ras mutation, enhanced
SCCA expression and IL-6 expression. These results indicate that SCCA is a Ras-responsive
factor that plays an important role in Ras-associated cytokine production and tumorigenesis.
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C
onstitutively active mutants of Ras are found in a large
number of human cancers1,2. Among the oncogenic
activities of mutant Ras, its ability to alter the tumour
microenvironment has been well appreciated with numerous
studies implicating Ras in various non-cell autonomous processes
including basement membrane degradation, immune cell
inﬁltration and angiogenesis3,4. This tumour microenvironment
altering function of Ras is at least partially caused by the ability of
Ras to induce the production and secretion of proinﬂammatory
and pro-tumorigenic cytokines. As cellular senescence has been
largely attributed to the cytokine secretory response termed
senescence-associated secretion phenotype (SASP)5,6, the
possibility remains that oncogene-induced secretory proﬁle is a
senescence-independent process on Ras activation. Several
reports have implicated Ras in the ability to modulate the
tumour microenvironment at least due in part to Ras’ ability to
promote the production of cytokines and chemokines such as
Interleukin (IL)-6, IL-8, granulocyte–macrophage-colony-
stimulating factor (GM-CSF) in a cell autonomous
manner3,4,7,8. Therefore, it remains to be determined whether
premature senescence is a prerequisite of oncogene-induced
secretory phenotype, and how Ras mechanistically regulates the
expression of the proinﬂammatory cytokines.
Squamous cell carcinoma antigens (SCCAs) are members
of the serpin family of endogenous protease inhibitors.
Approximately 98 and 92% homologous at their nucleotide and
amino-acid levels, respectively, SCCA1 (SerpinB3) and SCCA2
(SerpinB4) are ‘suicide-substrate’ protease inhibitors with differ-
ing substrate speciﬁcities because of amino-acid differences
within their reactive site loop domain9. Upregulated in
numerous cancers (the cervical, lung, head and neck, liver and
breast)10–13, both SCCA1 and SCCA2 are thought to promote cell
survival through the inhibition of cell death14,15. Moreover, the
level of SCCA has been shown to predict pathological grade,
disease stage, recurrence and response to both radiotherapy and
chemotherapy16–18. Despite SCCA’s well-reported involvement in
cancer, how SCCA is transcriptionally upregulated during
transformation and contributes to tumour development remains
largely unknown. Here, we study the oncogenic regulation of
SCCA and uncover a novel proinﬂammatory role for SCCA
downstream of mutant Ras. We demonstrate that through MAPK
signalling and the ETS transcription factor PEA3, oncogenic Ras
upregulates the expression of SCCA1/2 (SerpinB3/B4) to promote
inﬂammatory cytokine production and xenograft tumour growth.
Moreover, SCCA upregulation is observed in human colorectal
and pancreatic cancer. Our ﬁndings suggest an important role of
serpins in Ras-driven tumorigenesis.
Results
Oncogenic Ras upregulates SCCA expression. Elevated
expression of SCCA has been found in numerous human
cancers. However, the underlying molecular mechanism of its
upregulation remains unclear. We began to study this by
expressing several oncoproteins (HRasV12, myristolated-Akt
(myr-Akt), and c-Myc) in IMR90 primary human lung ﬁbro-
blasts. While myr-Akt and c-Myc failed to induce SCCA
expression, HRasV12 led to a marked increase in SCCA protein
levels (Fig. 1a). The SCCA antibody utilized was unable to
distinguish between the SCCA isoforms10, although quantitative
reverse-transcription PCR (qRT–PCR) analysis revealed an
increase in the transcript levels of both SCCA1 and SCCA2 in
response to RasV12 expression (Fig. 1b). This is not surprising
as the two SCCA isoforms are tandemly arranged on
human chromosome 18q and their promoters are highly
homologous19.
64 kDa Akt
Myc
Ras
SCCA
SCCA
Ve
ct
or
H
R
as
Ve
ct
or
H
R
as
Ve
ct
or
KR
as
Ve
ct
or
KR
as
Ve
ct
or
KR
as
β-Tubulin
β-Tubulin
Ve
ct
or
m
yr
-A
kt
c-
M
yc
H
R
as
Ve
ct
or
N
R
as
H
R
as
KR
as
Ras
SCCA
β-Tubulin
Ras
64 kDa
22 kDa
22 kDa 22 kDa
IMR90 BJ HT-29 Caco-2 HeLa
ERK1/2
P-ERK1/2
:P-ERK/T-ERK
β-Tubulin50 kDa
50 kDa
50 kDa
50 kDa
64 kDa
***
*
Vector
Ras
10,000
1,000
100
10
1
0.1R
el
at
iv
e 
ex
pr
es
sio
n 4-OHT: – –++
1.0
1.0 3.7 4.2 2.9
1.9 0.1
SCCA
ER:Ras
Day 12Da
y 
8
D
ay
 0
:SCCA/tubulin
50 kDa
50 kDa
50 kDa
50 kDa
50 kDa 50 kDa
ER:Ras Day 0
ER:Ras+OHT Day 8
ER:Ras+OHT Day 12
ER:Ras-withdraw
***
1.2
1.0
0.8
R
el
at
iv
e 
ex
pr
es
sio
n
0.6
0.4
0.2
0
SCCA1 SCCA2
SCCA1 SCCA2
***
Figure 1 | Oncogenic Ras upregulates SCCA expression. (a) Indicated oncogenes were stably expressed in IMR90 cells. Whole-cell lysates were obtained
and analysed by western blot with indicated antibodies. (b) Total RNA was extracted from vector-control or RasV12-expressing IMR90 cells. SCCA1
and SCCA2 transcript levels were analysed via qRT–PCR and normalized to that in vector-control cells. Data shown are meanþ s.e.m. of three independent
experiments performed in triplicate. (c,d) IMR90 cells expressing the ER:RasV12 fusion protein were treated with 4-OHT for 8 days, split and either cultured
in media containing 4-OHT or withdrew 4-OHT for additional 4 days. (c) Whole-cell lysates were analysed by western blot with indicated antibodies.
(d) Total RNA was extracted, and SCCA1 and SCCA2 transcript levels were analysed via qRT–PCR, and normalized to that of Day 12 ER:Ras with
4-OHT cells. Data shown are meanþ s.e.m. of three independent experiments performed in triplicate. (e) Indicated oncogenic Ras proteins were
stably expressed in IMR90 cells. Whole-cell lysates were obtained and analysed by western blot with indicated antibodies. (f) HRasV12 was stably
expressed in IMR90 and BJ cell lines. KRasV12 was stably expressed in HT-29, Caco-2 and HeLa cells. Whole-cell lysates were obtained and analysed
by western blot with indicated antibodies. *Po0.05; ***Po0.001 by t-test.
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To determine whether persistent Ras signalling is required for
SCCA expression, we used the oestrogen receptor (ER):RasV12
fusion protein that allows for RasV12 stabilization on the addition
of 4-hydroxytamoxifen (4-OHT) to the culture medium20. While
4-OHT induced the expression of Ras and SCCA (Fig. 1c),
removal of 4-OHT led to a drastic reduction in RasV12 protein
levels and diminished downstream signalling indicated by
decreased phospho-ERK, accompanied by a reduction of SCCA
at both protein and transcript levels (Fig. 1c,d), indicating that
sustained Ras signalling is required for maintaining SCCA
expression.
In addition to HRasV12, expression of KRasV12 or NRasQ61 also
resulted in elevated SCCA expression in IMR90 cells (Fig. 1e).
Similar to IMR90 cells, increased SCCA expression was observed
by expressing HRasV12 in the BJ primary human foreskin
ﬁbroblast cells, and by expression of KRasV12 in a number of
cancer cell lines with wild-type Ras, including the colon cancer
cell lines HT-29 and Caco-2, and HeLa cells (Fig. 1f). Taken
together, these results indicate that upregulation of SCCA
expression is a general feature of oncogenic Ras proteins in
various human cell lines.
It is important to note that in IMR90 and BJ ﬁbroblasts
expression of RasV12 elicits oncogene-induced senescence21. The
upregulation of SCCA in response to RasV12 in Caco-2, HT-29
and HeLa cells, which do not undergo senescence3,22, suggests
that upregulation of SCCA by RasV12 is independent of cellular
senescence. To further elucidate that the increased SCCA
expression is not a consequence of cellular senescence, we
induced premature senescence by treating IMR90 cells with
etoposide or H2O2 and replicative senescence by continually
passaging the cells. Indeed, unlike RasV12, these senescence-
inducing conditions failed to upregulate SCCA expression
(Fig. 2). These results indicate that expression of oncogenic Ras
stimulates expression of SCCA in a manner that is independent of
oncogene-induced senescence.
Ras-induced SCCA is dependent on the MAPK/PEA3 pathway.
To elucidate the mechanism by which RasV12 stimulates SCCA
expression, we used pharmacological inhibitors to selectively
inhibit MAPK and Akt pathways that are well characterized to be
activated by Ras2,23. While inhibition of Akt signalling had
little to no effect on SCCA expression (Fig. 3a,b), the MEK
inhibitor U0126 caused a marked inhibition of both SCCA1 and
SCCA2 transcription in both IMR90 (Fig. 3c,d) and HeLa
cells (Supplementary Fig. 1a,b). Similarly, expression of the
dominant-negative ERK2 blocked Ras-induced SCCA expression
(Supplementary Fig. 1c,d). Along the Ras/Raf/MAPK/ERK
pathway, expression of oncogenic BRafV600E also induced
SCCA expression (Supplementary Fig. 1e). We next sought to
identify which transcription factor may be mediating Ras-induced
expression of SCCA. The ETS transcription factor family member
PEA3 has been shown to be modulated by MAPK via
sumolyation24 and can activate SCCA transcription25. Indeed,
silencing of PEA3 in RasV12-expressing cells (Fig. 3e) resulted in a
drastic decrease of both SCCA1 and SCCA2 at protein and
transcript levels (Fig. 3f,g), without affecting MAPK signalling
indicated by similar levels of phospho-ERK in RasV12-expressing
cells (Fig. 3f). This PEA3-dependent SCCA expression was also
observed in RasV12-expressing HeLa cells (Supplementary
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Figure 2 | DNA damage-induced and replicative senescence fails to upregulate SCCA. (a,b) IMR90 cells were treated with vehicle-control, etoposide
(10mM) for 48 h, H2O2 (10mM) for 1 h, or stably transduced with HRasV12, then analysed 7 days post-treatment. (a) Cells were stained for b-Gal activity.
Representative images are shown. (b) Whole-cell lysates were analysed by western blot with indicated antibodies. (c,d) IMR90 cells were continuously
passaged and harvested at passage 15 as early passage (EP) or at passage 30 as late passage. (c) Cells were stained for b-galactosidase activity.
Representative images are shown. (d) Whole-cell lysates were analysed by western blot with indicated antibodies. Note that while all the conditions induce
cellular senescence, only RasV12 led to SCCA expression. Scale bar¼ 100mm.
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Fig. 2a–c) and was rescued by expression of wild-type murine
PEA3, but not by a PEA3 sumolyation-defective mutant24
(Supplementary Fig. 2d–f). These results indicate that mutant
Ras leads to SCCA upregulation via the MAPK/PEA3 pathway.
SCCA is essential for Ras-induced cytokine production. Next
we examined the biological role of elevated SCCA expression. We
chose to focus on using the IMR90 cell line that is widely used for
studying the effect of Ras activation during the early phase of
tumorigenesis. We began by examining the downstream signal-
ling pathways activated by oncogenic Ras (MAPK, Akt, NF-kB).
To this end, SCCA expression was silenced in RasV12-expressing
cells using two independent shRNA constructs that effectively
silenced both SCCA1 and SCCA2 (Fig. 4a), and the signalling
pathways examined by respective phosphorylation antibodies.
While loss of SCCA had little to no effect on the ability of mutant
Ras to activate Akt and MAPK phosphorylation (Fig. 4b), loss of
SCCA signiﬁcantly diminished RasV12-induced RelA/p65 phos-
phorylation that is indicative of NF-kB activation (Fig. 4b). This
effect was further conﬁrmed by utilizing a NF-kB luciferase
reporter construct (Fig. 4c).
Activation of NF-kB signalling has been attributed to cytokine
production downstream of Ras activation26. Indeed, inhibition
of NF-kB signalling using the pharmacological inhibitor BAY11-
7082 abrogated Ras-induced cytokine production in IMR90 and
HeLa cells (Supplementary Fig. 3). Therefore, we examined
whether SCCA plays a role in Ras-induced cytokine production
and performed a quantitative cytokine array analysis using cell
culture media. In agreement with literature5,6, RasV12-expressing
cells displayed a marked increase in a spectrum of cytokines
including IL-6, IL-8, CXCL1, G-CSF and GM-CSF (Fig. 4d).
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Figure 3 | SCCA upregulation is mediated by MAPK/PEA3. (a,b) Vector-control or HRasV12-expressing IMR90 cells were treated with either
vehicle-control or AKTi (10mM) for 24 h. (a) Whole-cell lysates were analysed by western blot with indicated antibodies. (b) Total RNA was extracted
and SCCA1 and SCCA2 transcript levels were analysed via qRT–PCR, and normalized to RasV12 cells treated with vehicle-control. Data shown are
meanþ s.e.m. of two independent experiments performed in triplicate. (c,d) Vector-control or HRasV12-expressing IMR90 cells were treated with
either vehicle-control (DMSO) or U1026 (MEKi, 10 mM) for 24 h. (c) Whole-cell lysates were analysed by western blot with indicated antibodies.
(d) Total RNA was extracted, and SCCA1 and SCCA2 transcript levels were analysed via qRT–PCR and normalized to that of Ras-expressing cells
treated with vehicle. Data shown are meanþ s.e.m. of three independent experiments performed in triplicate. (e–g) Vector-control or HRasV12-expressing
IMR90 cells were stably infected with lentiviral shNTC (non-target control) or shPEA3. (e) Successful silencing of PEA3 was conﬁrmed via qRT–PCR
and normalized to that in vector-control cells with shNTC. Data shown are meanþ s.e.m. of three independent experiments performed in triplicate.
(f) Whole-cell lysates were analysed through western blot with indicated antibodies. (g) Total RNA was analysed for the transcript levels of SCCA1
and SCCA2 via qRT–PCR and normalized to that in Ras-expressing cells with shNTC. Data shown are meanþ s.e.m. of three independent experiments
performed in triplicate. **Po0.01; ***Po0.001; NS, non-signiﬁcant by t-test.
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Consistent with the observed decrease in NF-kB signalling
(Fig. 4b,c), this increased cytokine expression was signiﬁcantly
abrogated on SCCA silencing (Fig. 4d,e). Quantitative RT-PCR
analysis revealed that the suppression of cytokine production was
due to transcriptional downregulation (Fig. 4f) and was rescued
by ectopically activating NF-kB signalling with TNFa treatment
(Fig. 4g). The SCCA-dependent NF-kB activation and cytokine
production downstream of oncogenic Ras were also observed in
HeLa and Caco-2 cells (Supplementary Fig. 4). The introduction
of oncogenic Ras in IMR90 elicits a DNA damage response that
has been reported to mediate cytokine production6,27. However,
silencing of SCCA had virtually no effect on Ras-induced DNA
damage indicated by the phosphorylation of H2A.X (Fig. 5a,b)
or the senescence-associated cell cycle arrest (Fig. 5c).
Taken together, these results indicate that SCCA plays an
essential role in Ras-mediated NF-kB activation and
inﬂammatory cytokine production that is independent of the
DNA-damage response.
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Figure 4 | SCCA modulates Ras-induced cytokine production. (a–f) Vector-control or HRasV12-expressing IMR90 cells were stably infected with lentiviral
shRNA control (shNTC) or two independent hairpins targeting SCCA. (a,b) Whole-cell lysates were analysed by western blot with indicated antibodies.
(c) Cells were transfected with an NF-kB luciferase reporter and a renilla luciferase construct. Twenty-four hours post transfection, cells were lysed
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SCCA promotes cytokine production by inducing the unfolded
protein response. We next sought to understand how SCCA
promotes Ras-mediated NF-kB activation and cytokine produc-
tion. A possible mechanism is through upregulation of the
unfolded protein response (UPR), which has been implicated in
mediating NF-kB activation and inﬂammatory transcriptional
programmes28. Our previous work showed that SCCA leads to
decreased lysosomal and proteasomal protein turnover, two
major protein degradation pathways, and hence increases the
steady-state level of ER stress29. Thus, we speculated that mutant
Ras induces ER stress through upregulation of SCCA. Indeed,
the ability of RasV12 to promote an ER stress response has
been reported30. Silencing of SCCA relieved the Ras-induced
inhibition of protein turnover as measured through total
ubiquitinated proteins (Fig. 6a). Furthermore, while RasV12 cells
showed a robust increase in UPR indicated by the appearance of
proteolytically cleaved ATF6 as well as both unspliced and spliced
XBP1, this response was signiﬁcantly reduced in SCCA-silenced
cells (Fig. 6b), indicating that SCCA mediates the UPR induced
by RasV12. Silencing of ATF6 or XBP1 in RasV12-expressing
cells (Fig. 6c) drastically diminished RasV12-induced cytokine
production (Fig. 6d–f; Supplementary Fig. 5) that was
accompanied by decreased RelA/p65 phosphorylation (Fig. 6g;
Supplementary Fig. 5). Conversely, ectopic expression of the
transcriptionally active spliced variant of XBP1 (XBP1s) restored
cytokine production in RasV12 cells when SCCA was silenced
(Fig. 6h,i). These results indicate that SCCA modulates cytokine
production downstream of mutant Ras by stimulating UPR.
SCCA is upregulated in colorectal and pancreatic cancers. Our
results thus far show that SCCA is a Ras-responsive gene that
plays an essential role in Ras-induced cytokine production. We
next sought to identify an in vivo connection between Ras
and SCCA expression. Using TCGA (The Cancer Genome Atlas)
data of human colorectal cancer, which were available with
sizeable samples with the KRas mutation, we identiﬁed a positive
correlation between the presence of mutant Ras and SCCA
upregulation (Fig. 7a). We also chose to examine pancreatic
ductal adenocarcinoma (PDAC), where the mutant KRas func-
tions as the primary driver31. It also offers a unique model where
the precursor lesions to PDAC have a deﬁned pathological
progression31. To this end, we analysed the pancreatic cancer
gene expression data sets for SCCA expression through
Oncomine. In the seven available patient data sets, SCCA1
mRNA was upregulated in six and SCCA2 mRNA in three
independent data sets32–37 (Fig. 7b–d). Of note, the Logsdon data
set37 identiﬁed both SCCA1 and SCCA2 to be upregulated in
pancreatic cancer when compared with chronic pancreatitis
(Fig. 7d). To further examine the association of SCCA expression
in human pancreatic cancer, we performed immunohisto-
chemistry (IHC) for SCCA using a pancreatic cancer tissue
microarray. While all non-neoplastic/normal pancreatic samples
were negative for SCCA expression, positive staining for SCCA
was seen throughout all stages of pancreatic cancer progression.
The incidence of SCCA positivity increased in relation to the
progression of pancreatic cancer: 2 out of 17 (11.8%) PanIN-1
lesions, 5 out of 19 (26.3%) PanIN-2 lesions, 8 out of 15 (53.3%)
PanIN-3 lesions and 20 out of 30 (66.7%) of PDAC (Fig. 7e;
Po0.001). Moreover, consistent with the result that SCCA
promotes inﬂammatory cytokine production in cultured cells,
IHC of IL-6 on the same panel of pancreatic tissues showed a
positive correlation between IL-6 and SCCA in both PDAC
(Fig. 7f,g) and PanIN (Supplementary Fig. 6) samples.
Endogenous SCCA promotes IL-6 production and tumor-
igenesis. To further explore the physiological relevance of SCCA,
we tested the expression and function of SCCA in a setting when
mutant Ras is expressed at endogenous levels. RasV12 failed to
induce the expression of the SCCA paralogues Serpinb3a or Ser-
pinb3b in immortalized MEF NIH3T3 (Supplementary Fig. 7a) or
in primary MEFs (Supplementary Fig. 7b). The failure to detect
upregulation of SCCA paralogues in the murine system prevented
us from using the well-established LSL-KRas mouse model38.
Hence, we instead examined a panel of human pancreatic cancer
cell lines that harbour the mutant KRas. We found ﬁve out of nine
cell lines to be positive for SCCA expression (Fig. 8a). In the cell
lines that displayed detectable levels of SCCA and can tolerate loss
of KRas (CFPAC-1, L3.6 and Capan-1), silencing of mutant KRas
signiﬁcantly reduced SCCA expression (Fig. 8b). Consistent with
the essential role of SCCA in Ras-mediated cytokine production,
silencing of SCCA in three SCCA-positive cell lines resulted in
decreased expression of IL-6, whereas the SCCA shRNAs did not
affect IL-6 expression in the SCCA-low PANC-1 cells (Fig. 8c).
Moreover, while silencing of SCCA in CFPAC-1, L3.6 and HPAF-II
cells did not compromise cell proliferation in cell culture
(Supplementary Fig. 8), it led to impaired xenograft tumour
growth in all three cell lines (Fig. 8d). These results, taken together
with the above ﬁnding that SCCA positivity correlates with
progression of pancreatic cancer development (Fig. 7e), indicate
that SCCA expression is under the control of mutant Ras expressed
at endogenous level, and that the SCCA-mediated inﬂammatory
response plays a pro-tumorigenic role in Ras-driven cancer.
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Discussion
In this study, we show that the endogenous serine/cysteine
proteinase inhibitor SCCA is upregulated on activation of
oncogenic Ras, in a manner that is dependent on hyper-active
MAPK signalling and the ETS transcription factor PEA3.
Downstream of oncogenic Ras, SCCA promotes activation of
NF-kB signalling and cytokine production by blocking protein
turnover and inducing the UPR.
Our study implicates SCCA as a direct link between oncogenic
Ras mutation, NF-kB activation and cytokine production.
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While it has been clearly demonstrated that the mutant Ras can
activate NF-kB and induce inﬂammatory cytokine production in
various settings, the underlying molecular mechanism has
remained elusive. In numerous settings, inﬂammatory cytokine
production has been attributed to oncogene-induced senescence
that is associated with excess production of reactive oxygen
species and subsequent DNA damage or loss of p53 (refs 6,27).
We found that oncogenic Ras upregulates SCCA to promote
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Figure 7 | SCCA is upregulated in human colorectal and pancreatic cancer. (a) TCGA human colorectal cancer data of somatic mutation and RNA
expression from Broad Institute’s Genome Data Analysis Center were analysed. There were 207 human colorectal tumours that have both somatic
mutation and mRNA expression data available. KRas was mutated in 87 out of the 207 samples. By comparing SCCA mRNA expression level of the groups
with wild-type and mutated KRas, SCCA expression was found to be signiﬁcantly higher in the group with KRas mutation. Boxplots with whisker from 10 to
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pancreatic tissue and pancreatic cancer, or for SCCA1 and SCCA2 mRNA expression levels in chronic pancreatitis and pancreatic cancer (d). The boxes
represent the interquartile range. Whiskers represent the 10th–90th percentile range. Bars represent the median. P-values were calculated by two-sample
t-test. (e–g) IHC against SCCA and IL-6 was performed on the corresponding serial pancreatic tissue microarrays. (e) Representative images of
normal pancreatic tissue and SCCA-positive PanIN 1, PanIN-2, PanIN-3 and PDAC samples are shown; scale bar, 100mm. (f) Representative images of
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cytokine production, whereas SCCA is not upregulated in the
setting of drug-induced and replicative senescence. These results
suggest that the secretory response seen in cells with oncogenic
Ras mutations may be distinct from SASP induced by DNA
damage or loss of p53. Although the physiological signiﬁcance of
Ras-induced cellular senescence remains an open topic, our
results show that Ras can induce SCCA expression in cells where
Ras does not induce senescence (Fig. 1f). Furthermore, we found
that SCCA-dependent cytokine production occurs in human cells
expressing endogenous level of mutant Ras (Fig. 8) and this
provides a mechanism that uncouples cellular senescence
from inﬂammatory cytokine production on Ras activation.
Importantly, our study shows that the incidence of SCCA
positivity within PanIN lesions and PDAC increases with disease
progression (Fig. 7e). Therefore, monitoring SCCA levels may
become an attractive diagnostic tool in pancreatic cancer patients,
as the levels of SCCA have been used in numerous studies to
successfully predict disease stage and response to therapy16–18.
Our work uncovers SCCA as a critical mediator of Ras-induced
UPR. Until now, SCCA’s involvement in cancer was largely
attributed to its protective role against lysosomal permeability
that leads to unscheduled activation of lysosomal proteases29,39.
We have previously reported that, through its protease inhibitory
activity, SCCA leads to a decrease in both lysosomal and
proteasomal protein turnover and elicits a non-lethal level of ER
stress response29. It remains to be determined how SCCA
mechanistically suppresses protein turnover, and whether other
functions of SCCA such as its possible role in the nucleus
contribute to increased UPR. Nevertheless, here we show that
SCCA-mediated UPR plays a critical role in the context of
oncogenic Ras mutation. Enhanced UPR has been well implicated
in cancer, largely owing to the highly proliferative status of cancer
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cells and their encounter of growth limiting conditions such as
nutrient deprivation and hypoxia40,41. Targeting the enhanced
UPR of cancer cells remains an attractive therapeutic option,
although the precise prediction of sensitivity has been difﬁcult.
Consistent with this notion, tumours driven by the mutant Ras
have been shown to be susceptible to proteotoxic therapies42. Our
current work showing that SCCA expression is stimulated by
oncogenic Ras and plays an essential role in Ras-induced ER
stress response, together with our previous report demonstrating
SCCA sensitizes cells to proteotoxic stress29, suggest that SCCA
may be a valuable predictor of response to proteotoxic agents in
tumours harbouring oncogenic Ras.
The contribution of the tumour stroma and inﬂammation to
tumour development and progression, especially in pancreatic
and colorectal cancer, is well accepted43,44. While NF-kB
signalling has been shown to mediate the SASP response26,
it is critical for the development of Ras-driven lung
adenocarcinoma45. The pro-tumorigenic role of SCCA
mediating NF-kB activation and inﬂammatory cytokine
production is consistent with these reports. This adds a new
pro-tumour mechanism of SCCA in addition to its well-
documented anti-cell death function15,46–49. In a parallel study,
we ﬁnd that ectopic expression of SCCA can independently
promote the transformation of the non-tumorigenic mammary
epithelial cell line MCF10A (Sheshadri et al., in preparation).
As numerous studies utilizing anti-inﬂammatories to target the
tumour microenvironment have shown great promise in the
treatment of malignancies50,51, the ability of SCCA to promote
cytokine production and tumorigenesis suggests a therapeutic
value of targeting its protease inhibitory activity.
Methods
Cell lines and culture. 293T, IMR90, BJ, HT-29, Caco-2, HeLa, AsPC-1, Capan-1,
Capan-2, CFPAC-1, HPAF-II, L3.6, PANC-1, PL45 and S2-013 cells were cultured
according to ATCC recommendations. 293T, HeLa, PANC-1, PL45 and S2-013
cells were cultured in DMEM supplemented with 10% FBS (HyClone). IMR90,
BJ and HPAF-II cells were cultured in MEM supplemented with 10% FBS. HT-29
and Capan-2 cells were cultured in McCoy’s 5a supplemented with 10% FBS.
Caco-2 cells were cultured in MEM supplemented with 20% FBS. AsPC-1 and L3.6
cells were cultured in RPMI supplemented with 10% FBS. Capan-1 cells were
cultured in Iscove’s supplemented with 20% FBS. CFPAC-1 cells were cultured in
Iscove’s supplemented with 10% FBS. All media were supplemented with 100 units
per ml penicillin and 100 mgml 1 streptomycin (Invitrogen).
Plasmids and reagents. Retroviral expression vectors for WZL-hygro and
WZL-HRasV12 were a kind gift of Dr Alea Mills at Cold Spring Harbor
Laboratory21. pBABE-puro and pBABE-KRasV12 were a kind gift of Dr Scott Lowe
at Memorial Sloan-Kettering Cancer Institute. pBABE-NRasQ61 was purchased
from Addgene (Dr Channing Der; Plasmid 12543)52. pLNCX-ER:HRasV12 was a
kind gift of Dr Masashi Narita at University of Cambridge20. pcDNA3-FLAG-
ERK2-WT and pcDNA3-FLAG-ERK2-T138A (DN) were a kind gift of Dr Scott
Eblen at the Medical University of South Carolina53. pcDNA3-PEA3-WT and
pcDNA3-PEA3-K123R (MUT) were a kind gift of Dr Andrew Sharrocks at the
University of Manchester24. Human XBP1s was cloned by RT-PCR from total
RNA from IMR90 cells. Primers used were as follows, forward with HindIII
restriction and FLAG tag: 50-AAGCTTATGGATTACAAGGATGACGATGAC
AAGTGGTGGTGGCAGCCGCGCCGAACCC-30 and reverse primer with HindIII
restriction site: 50-AAGCTTTTAGACACTAATCAGCTGGGGAAAG-30. The RT-
PCR product was digested with HindIII and ligated into the pLPC retroviral
expression vector. All shRNA lentiviral constructs were in the pLKO (Sigma)
backbone. shRNA targeting sequences used are shGFP: 50-TACAACAG
CCACAACGTCTAT-30 ; shScramble: 50-CAACAAGATGAAGAGCACCAA-30;
shSCCA#1: 50-GCACAACAGATTAAGAAGGTT-30 ; shSCCA#2: 50-CCGCTGTA
GTAGGGATTCGGAT-30 ; shPEA3: 50-GCTCCGATACTATTATGAGAA-30;
shATF6: 50-GCAGCAACCAATTATCAGTTT-30 ; shXBP1: 50-GCCTGTCTGTA
CTTCCATTCAA-30; shKRas: 50-CAGTTGAGACCTTCTAATTGG-30 . Bay-11-
7082 (B5556), 4-hydroxytamoxifen (H7904) and crystal violet (C0775) were
purchased from Sigma. U0126 (V1121) was purchased from Promega. AKT
inhibitor VIII (124018) was purchased from Calbiochem. TNFa (210-TA) was
purchased from R&D Systems. X-gal (15520-018) was purchased from Invitrogen.
Etoposide (8154-1) was purchased from Clontech.
DNA transfection and viral infection. Both retrovirus and shRNA lentivirus were
generated in 293T cells. In brief, 293T were transfected by Lipofectamine 2000
(Invitrogen) with the plasmid of interest, packaging plasmid, and a plasmid
encoding for the VSV-G envelope protein. Forty-eight and seventy-two hours after
initial transfection, viral supernatant was collected, ﬁltered, supplemented with
polybrene (10 mgml 1) and used to infect target cells. Forty-eight hours after last
infection, cells were selected with appropriate antibiotics. IMR90 cells were selected
for 2 days with 100 mgml 1 of hygromycin, 2 mgml 1 of puromycin or
1.75mgml 1 of G418. HeLa and L3.6 cells were selected with 0.5 mgml 1 of
puromycin for 2 days. Caco-2, Capan-1, CFPAC-1 and PANC-1 cells were selected
with 1.0 mgml 1 of puromycin for 3 days.
Immunoblot analysis. Cell lysates were prepared in RIPA buffer (1% sodium
deoxycholate, 0.1% SDS, 1% Triton X-100, 0.01M Tris pH 8.0, 0.14M NaCl).
Protein expression was examined by western blotting using antibodies against
SCCA1/2 (FL-390; Santa Cruz; 1:1,000), Ras (Clone Ras10; Millipore; 1:10,000),
p21 (C-19; Santa Cruz; 1:500), ERK1/2 (4,695; Cell Signaling; 1:10,000), P-ERK1/2
(4,370; Cell Signaling; 1:2;000), Akt (9,272; Cell Signaling; 1;2,000), P-Akt (4,058;
Cell Signaling; 1:2,000), P-RelA/p65 (3,031; Cell Signaling; 1;1,000), RelA/p65 (F-6;
Santa Cruz; 1:2,000), ATF6 (F-7; Santa Cruz; 1:500), XBP1 (M-186; Santa Cruz;
1:500), Ubiquitin (P4D1; Covance; 1:1,000) and b-tubulin (Sigma; 1:10,000). All
primary antibodies were incubated overnight at 4 C. Horseradish peroxidase or
Alexaﬂuor-conjugated goat anti-rabbit (Rockland) or goat anti-mouse (Rockland)
antibodies were used as secondary antibodies (1:2,000). Western blots were
developed using an ECL detection kit (Thermo Scientiﬁc) or an Odyssey Imager
(LI-COR). Full scans of uncropped blots can be found in Supplementary Figs 9,10.
Gene expression analysis and quantitative PCR. Total RNA was isolated and
puriﬁed using the RNeasy kit (Qiagen). cDNA was obtained by reverse transcribing
1–2 mg of total RNA using SuperscriptIII Reverse Transcriptase (Invitrogen) and
used for qPCR. qPCR reactions were performed in triplicate using SYBR Green
reagents (Quanta Biosciences) on a StepOnePlus (Life Technologies). GAPDH was
used as an endogenous control. All results were normalized to GAPDH. Primer sets
used are: GAPDH: 50-AAGGTCGGAGTCAACGGATTT G-30 and 50-CCATGGG
TGGAATCATATTGGAA-30 ; SCCA1: 50-AGCCGCGGTCTCGTGC-30 and
50-GGCAGCTGCAGCTTCTG-30 ; SCCA2: 50-AGCCACGGTCTCTCAG-30 and
5-GCAGCTGCAGCTTCCA-30 ; Serpinb3a: 50-CATTTGTTTGCTGAAGCCAC
TAC-30 and 50-CATGTTCGAAATCCAGTGATTCC-30 ; Serpinb3b: 50-ATTCGT
TTTCATGCAGCTGATGT-30 and 50-GAAAGCTGAAGTTAAATTTGTTCG-30 ;
PEA3: 50-GGACTTCGCCTACGACTCAG-30 and 50-CGCAGAGGTTTCTCA
TAGCC-30; IL-6: 50-TCCACAAGCGCCTTCGGTCCA30 and 50-AGGGCTGA
GATGCCGTCGAGGA-30 ; IL-8: 50-AAGGAAAACTGGGTGCAGAG-30 and
50-ATTGCATCTGGCAACCCTAC-30 ; CXCL1: 50-CACCCCAAGAACATCCA
AAG-30 and 50-TAACTATGGGGGATGCAGGA-30; G-CSF: 50-ACTACAAGCA
GCACTGCCCT-30 and 50-AGCAGTCAAAGGGGATGACA-30 ; GM-CSF: 50-CAA
GTGAGGAAGATCCAGGG-30 ; and 50-AGAGAGTGTCCGAGCAGCAC-30 .
Cytokine array. Cells were washed once with PBS and incubated for 8 h with fresh
media. Supernatant was collected, cleared by centrifugation and used immediately.
The amount of supernatant used was normalized to cell number and used with the
human cytokine array kit (R&D Systems). IRDye 800CW Streptavidin (Rockland)
was used as secondary (1:2,000) and arrays were imaged and quantiﬁed on an
Odyssey Imager.
Senescence assays. Senescence was induced by oncogenic Ras, etoposide
(100 mM, 48 h), H2O2 (100 mM, 1 h) or long-term passaging (replicative senes-
cence). All cells were analysed 7 days post-selection or post-treatment. For
SA-b-gal staining, cells were ﬁxed in 2% formaldehyde, 0.2% glutaraldehyde in PBS
for 15min and stained (150mM NaCl, 2mM MgCl2, 5mM K3Fe(CN)6, 5mM
K4Fe(CN)6, 40mM NaPi, pH 6.0, 1 mgml 1 X-Gal) overnight at 37 C. For BrdU
staining, cells were cultured with BrdU (10 nM) for 6 h, ﬁxed with acid ethanol
(90% ethanol, 5% acetic acid, 5% H2O) for 30min at room temperature. Cells were
then washed once with PBS, incubated with 2M HCl for 20min, 0.1M sodium
borate, pH 8.5 for 2min and washed once with PBS. Cells were blocked in 10%
bovine serum albumin (BSA) in PBS for 1 h at room temperature and incubated
with anti-BrdU (BD Pharmingen, 1:500 in 5% BSA in 0.1% PBS-tween) overnight
at 4 C. Cells were washed, incubated with anti-mouse Alexa-594 (1:500) for 1 h at
room temperature, washed, co-stained with 40 ,6-diamidino-2-phenylindole (DAPI)
and mounted.
NF-jB luciferase activity assay. NF-kB activity was determined by using an
NF-kB luciferase reporter construct where the luciferase gene is under control of
the IL-6 promoter and internal control plasmid pCMV-RL using a dual-luciferase
reporter system (Promega). Cells were plated 24 h before transfection at 5 104
cells per well of 24-well plate. NF-kB-luciferase vector (250 ng) and 100 ng
pCMV-RL were used for transfection. Twenty-four hours post transfection, cells
were washed with PBS and lysed in 100 ml passive lysis buffer for 10min. Luciferase
activity was determined following the manufacturer’s recommended protocol with
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a SpectraMax M5 Microplate Reader. The ratios of ﬁreﬂy luciferase versus renilla
luciferase are used as relative luciferase activities.
TCGA analysis. TCGA human colorectal cancer (study abbreviation:
COADREAD) data were downloaded from Broad Institute’s Genome Data
Analysis Center (GDAC). Standard data of somatic mutations (Mutation_
Packager_Calls_Level_3) and RNA expression (Merge_transcriptome__
agilentg4502a_07_3__unc_edu__Level_3__unc_lowess_normalization_gene_
level__data.Level_3) were used. There were 207 human colorectal tumours that
have both somatic mutation and mRNA expression data available. KRas was
mutated in 87 out of the 207 samples. SCCA mRNA expression level was compared
between the groups with wild-type and mutant KRas.
Immunohistochemistry. Tissue microarrays came from the Vanderbilt GI SPORE
Tissue Core. Distribution and the use of all human samples were approved by the
Institutional Review Boards of Vanderbilt University Medical Center and Stony
Brook University, and samples were obtained with informed consent. IHC was
performed on a Ventana XT (Tucson, AZ, USA) autostainer, according to the
manufacturer’s directions.
Tissue microarray analysis. Damaged core spots and those that did not contain
cancerous tissue were eliminated from scoring. The sections were scored inde-
pendently by two evaluators blinded to the clinical status of the patients. Samples
were scored as previously described10. In brief, samples were scored as percent of
tumour cells with SCCA or IL-6 expression: 0, no expression; 1,o10%; 2, 10–50%;
3, 450%. For SCCA, a score Z1 was considered positive. For IL-6, 0, negative; 1,
weak; 2, moderate; 3, strong.
Xenograft tumour experiments. Male athymic nude mice, 6- to 8 weeks old, were
obtained from Taconic Farms. Mice were housed and monitored at the Division of
Laboratory Animal Resources at Stony Brook University. All experimental proce-
dures and protocols were approved by the Stony Brook University institutional
animal care and use committee (IACUC). Tumours were established by
resuspending 1 106 tumour cells in 100ml PBS and injecting the cells into the
mid-ﬂanks of mice using a 26-gauge needle. For each tumour, the tumour length (l)
and width (w) was measured every 4–5 days with an electronic caliper. Tumour
volume (v) was calculated using the formula v¼ (lw2)/2 and plotted in mm3.
Statistical analysis. Statistical analyses were performed with GraphPad Prism
(Graphpad Software Inc). For gene expression, luciferase activity and xenograft
tumour growth signiﬁcance was calculated with t-tests. w2-tests were used to
assess statistical signiﬁcance of various categorical clinical features between
SCCA-negative and SCCA-positive samples. For the TCGA colorectal cancer data
analysis, Wilcoxon Rank Sum test was performed. For all tests, P-values were
considered statistically signiﬁcant when o0.05.
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